Related Experiment Videos
Transgenic small interfering RNA halts amyotrophic lateral sclerosis in a mouse model
Yuki Saito1, Takanori Yokota, Tasuku Mitani
1Department of Neurology and Neurological Science, Graduate School, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519.
The Journal of Biological Chemistry
|October 14, 2005
Summary
Small interfering RNA (siRNA) gene silencing effectively reduced toxic mutant SOD1 protein production in a mouse model of familial amyotrophic lateral sclerosis (ALS). This approach prevented disease development, demonstrating siRNA
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Autosomal dominant diseases, like familial ALS, can stem from missense point mutations causing toxic protein production.
- Reducing the expression of mutated genes is a potential therapeutic strategy for improving disease phenotype.
Purpose of the Study:
- To investigate the efficacy of modified small interfering RNA (siRNA) for in vivo gene silencing of the SOD1 gene in a mouse model of familial ALS.
- To assess the long-term knockdown effect of transgenic siRNA and its impact on disease progression.
Main Methods:
- Generation of transgenic (Tg) mice with modified anti-SOD1 siRNA designed to prevent the shutdown phenomenon.
- Crossing anti-SOD1 siRNA Tg mice with SOD1G93A Tg mice (a model for ALS).
- Monitoring SOD1 expression and disease development in the central nervous system.
Main Results:
- The modified siRNA demonstrated a sustained in vivo knockdown effect on SOD1 expression across four generations.
- Crossing with SOD1G93A Tg mice resulted in the prevention of ALS development.
- Mutant G93A SOD1 production in the central nervous system was inhibited by the siRNA.
Conclusions:
- siRNA-mediated gene silencing is a viable strategy for halting the progression of familial ALS caused by SOD1 mutations.
- This study provides proof of principle for using siRNA therapeutics in neurodegenerative diseases.